NASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis $15.60 +0.32 (+2.09%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$15.57 -0.03 (-0.17%) As of 05:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AUPH alerts:Sign Up Key Stats Today's Range$15.15▼$15.6550-Day Range$13.95▼$16.4252-Week Range$7.28▼$16.88Volume1.21 million shsAverage Volume1.25 million shsMarket Capitalization$2.01 billionP/E Ratio7.19Dividend YieldN/APrice Target$17.25Consensus RatingHold Company Overview Aurinia Pharmaceuticals Inc. is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline. The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S. Food and Drug Administration for the treatment of adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus. Beyond lupus nephritis, Aurinia is investigating voclosporin in additional indications such as focal segmental glomerulosclerosis (FSGS) and dry eye disease, with several ongoing clinical trials to evaluate safety and efficacy. Founded in the early 1990s, Aurinia is headquartered in Victoria, British Columbia, and maintains a presence in North America to support its clinical and commercial activities. The company’s leadership team comprises experienced professionals in drug development, regulatory affairs and commercial operations, guiding Aurinia through pivotal clinical milestones and into its initial product launch. As Aurinia continues to expand its pipeline and explore partnerships, it remains committed to addressing unmet needs in autoimmune disease management.AI Generated. May Contain Errors. Read More Aurinia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreAUPH MarketRank™: Aurinia Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat, and ranked 468th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialAurinia Pharmaceuticals has a consensus price target of $17.25, representing about 10.6% upside from its current price of $15.60.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Aurinia Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-2.44% Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to decrease by -2.44% in the coming year, from $0.82 to $0.80 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is 7.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is 7.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.86.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 3.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Aurinia Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.87% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.68.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently decreased by 2.47%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.8 / 5News SentimentN/A News SentimentAurinia Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest10 people have searched for AUPH on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.MarketBeat Follows5 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $7,224,982.00 in company stock, which represents 0.3601% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,224,982.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.Read more about Aurinia Pharmaceuticals' insider trading history. Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AUPH Stock News HeadlinesWe Believe Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings Are A Poor Guide For Its ProfitabilityMay 15, 2026 | finance.yahoo.comParabolic AI rally has bulls eyeing a comeback for this one-time meme metal tradeMay 11, 2026 | cnbc.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 19 at 1:00 AM | Paradigm Press (Ad)RBC Capital Sticks to Their Hold Rating for Aurinia Pharmaceuticals (AUPH)May 11, 2026 | theglobeandmail.comAurinia Pharmaceuticals Inc. Just Beat EPS By 28%: Here's What Analysts Think Will Happen NextMay 9, 2026 | finance.yahoo.comAUPH stock sees biggest single-day drop in more than 9 months despite Q1 earnings beat – here’s what’s spooking investorsMay 7, 2026 | msn.comAurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business ProgressMay 7, 2026 | financialpost.comFAurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value RightMarch 30, 2026 | financialpost.comFSee More Headlines AUPH Stock Analysis - Frequently Asked Questions How have AUPH shares performed this year? Aurinia Pharmaceuticals' stock was trading at $15.95 at the beginning of the year. Since then, AUPH stock has decreased by 2.2% and is now trading at $15.60. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.07. The biotechnology company had revenue of $77.71 million for the quarter, compared to analysts' expectations of $76.98 million. Aurinia Pharmaceuticals had a net margin of 99.97% and a trailing twelve-month return on equity of 26.62%. Who are Aurinia Pharmaceuticals' major shareholders? Aurinia Pharmaceuticals' top institutional shareholders include Arrowstreet Capital Limited Partnership (2.55%), Renaissance Technologies LLC (1.29%), Rice Hall James & Associates LLC (0.38%) and Bank of New York Mellon Corp (0.26%). Insiders that own company stock include Kevin Tang, Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Greg Keenan, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/07/2026Today5/18/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 AUPH's financial health is in the Green zone, according to TradeSmith. AUPH has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AUPH CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year Founded2013Price Target and Rating Average Price Target for Aurinia Pharmaceuticals$17.25 High Price Target$21.00 Low Price Target$15.00 Potential Upside/Downside+10.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$2.17 Trailing P/E Ratio7.19 Forward P/E Ratio19.02 P/E GrowthN/ANet Income$287.20 million Net Margins99.97% Pretax Margin44.83% Return on Equity26.62% Return on Assets19.65% Debt Debt-to-Equity Ratio0.08 Current Ratio5.55 Quick Ratio5.01 Sales & Book Value Annual Sales$283.05 million Price / Sales7.09 Cash Flow$1.03 per share Price / Cash Flow15.08 Book Value$4.41 per share Price / Book3.54Miscellaneous Outstanding Shares128,600,000Free Float112,913,000Market Cap$2.01 billion OptionableOptionable Beta1.44 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:AUPH) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
